Go-ahead for Possis stroke trials:
This article was originally published in Clinica
Executive Summary
Possis Medical has the go-ahead for US trials of its AngioJet clot-busting system for treating stroke caused by blocked carotid arteries. Feasibility studies will consist of 10 patients at two sites. The company has filed a humanitarian device exemption application with the FDA to sell its Perma-Flow coronary bypass graft to a limited number of patients. This will not necessitate new trials of the device as reported in Clinica No 782, p 19.